Warberg Asset Management’s BriaCell Therapeutics Warrant expiring 2031 BCTXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$211K Buy
181,612
+22,057
+14% +$20.7K 0.03% 130
2026
Q2
$142K Buy
159,555
+44,555
+39% +$41.2K 0.03% 129
2026
Q1
$118K Buy
+115,000
New +$122K 0.02% 134

Other funds holding BCTXL

Warberg Asset Management's BCTXL Position: Q3 2026 in Review

Warberg Asset Management increased its BriaCell Therapeutics Warrant expiring 2031 (BCTXL) stake by 14% in Q3 2026, buying an estimated $20.7K and bringing the position to 181,612 shares worth $211K. The position accounts for 0.03% of the portfolio, ranked #130.

Warberg Asset Management first reported a position in BCTXL in Q1 2026 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold BCTXL as of Q3 2026.

  • Warberg Asset Management held 181,612 shares of BriaCell Therapeutics Warrant expiring 2031 worth $211K as of Q3 2026.
  • Warberg Asset Management bought 22,057 BriaCell Therapeutics Warrant expiring 2031 shares in Q3 2026, an estimated $20.7K.
  • BriaCell Therapeutics Warrant expiring 2031 made up 0.03% of Warberg Asset Management's portfolio in Q3 2026, its #130 holding.
  • Warberg Asset Management first reported a position in BriaCell Therapeutics Warrant expiring 2031 in Q1 2026 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant expiring 2031 as of Q3 2026.

Based on Warberg Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.